FDA Brief

Warning letters Drugs

FDA warning letter to

Alternative Health Distribution LLC d/b/a CannaAid

High riskIssued Nov 1, 2022Posted Nov 2, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned CannaAid over website claims that CBD/cannabinoid products prevent or treat COVID-19.

What happened

FDA reviewed https://www.cannaaidshop.com/ on October 5, 2022, and FTC reviewed it on October 7, 2022. The site offered CBD and cannabinoid products with claims that they could mitigate, prevent, treat, diagnose, or cure COVID-19. FDA said the products were unapproved new drugs (sold without FDA approval) and misbranded drugs (drug labeling/claims violations).

What FDA found

  1. The CBD/cannabinoid products are unapproved new drugs because they were sold with COVID-19 treatment or prevention claims without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded drugs because their labeling or claims violate the FD&C Act.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company may not ship these products across state lines.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The website made COVID-19 prevention or treatment claims without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. The company made deceptive COVID-19 treatment, cure, prevention, or mitigation claims that can bring civil penalties.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks the company to immediately stop selling unapproved products for COVID-19 and, within 48 hours, email the specific steps taken to COVID-19-Task-Force-CDER@fda.hhs.gov; FTC asks for a 48-hour certification that the unsubstantiated claims have ceased.

Who should pay attention

  • CBD and hemp product sellers making health claims
  • companies marketing supplements with COVID-19 claims
  • advertising and compliance teams for wellness brands

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk